Enfortumab vedotin and radiation for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It is for people with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer (stage T2-T4a) that has not spread to lymph nodes or other organs.
- You cannot receive cisplatin chemotherapy due to kidney problems, nerve damage, hearing loss, heart failure, or you chose not to take it.
- You have not had chemotherapy or radiation for bladder cancer before, though prior treatments placed directly into the bladder (like BCG) are okay.
- Your daily activity level is fully active or able to do light work (ECOG 0-1).
- You are not on dialysis for kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat muscle-invasive bladder cancer. The goal is to see if this can help patients avoid having their bladder removed. It is for people who cannot or choose not to have surgery.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.